Human Genome Sciences and their partner GlaxoSmithKline announced this week that its drug BENLYSTA™ (belimumab) met its primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).
Now... if you're like me and find anything too scientific difficult to absorb, I've added a few links here explaining the importance of this news.
Firstly, there's the video above where William W. Freimuth, M.D., Ph.D. Vice President, Human Genome Sciences explains a little more about the research and drug trial.
Also LFA President & CEO Sandra C. Raymond comments on the first potential lupus treatment in 50 Years via another video message.
Then there's this article written in The Washington Post.
The Alliance For Lupus Research also has some information regarding this important news which is available by clicking here.




